Xu, Lei
Merck & Co., Inc., Rahway, NJ, USA (United States)
4 papers on CoChatORCID 0000-0002-9241-7019
Most cited papers
- Verified
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics
Cited by 2,552
- Verified
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 614
- Verified
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
Maio, M., Ascierto, P. A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P. A., Bariani, G. M., De Jesus Acosta, A., Doi, T., Longo, F., et al. (2022) · Annals of Oncology
Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer
Cited by 472
- Verified
Effects of mobile phone application combined with or without self‐monitoring of blood glucose on glycemic control in patients with diabetes: A randomized controlled trial
Yu, Y., Yan, Q., Li, H., Li, H., Wang, L., Wang, H., Zhang, Y., Xu, L., Tang, Z., Yan, X., et al. (2019) · Journal of Diabetes Investigation
Mobile Health and mHealth ApplicationsDiabetes Management and Research
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free